Electronic cigarette use in lung cancer patients

标题：电子烟在头颈癌和肺癌患者中的使用 项目总结/摘要 该提案的总体目标是促进西奥多布拉斯基博士发展成为一个既定的， 烟草控制独立调查员。对于这项研究，他将重点放在癌症患者和影响 电子烟（电子烟）对吸烟，戒烟和健康结果的影响。经确定 吸烟在许多方面对癌症患者产生不利影响。电子烟有可能减少 吸烟暴露、相关毒性和促进戒烟。然而，几乎没有研究 是为了证实这一假设Brasky博士是一位癌症流行病学家，也是俄亥俄州的成员 大学综合癌症中心（OSUCCC）在分析和治疗方面具有相当的专业知识， 纵向数据的解释。由于强大的制度环境，他一直参与 在过去几年中，各种烟草研究项目。他对此感到兴奋， 利用与电子烟有关的烟草控制的特殊机会。拟议的培训计划 将使他能够获得烟草研究方面的专业知识和经验（例如，烟草管制课程 科学），干预研究（例如，临床研究方法和转化行为课程 研究）和补充研究中的原始数据收集。这项培训将利用特殊的 俄勒冈州立大学的制度环境和一位经验丰富的烟草控制导师Peter Shields博士，副 OSUCCC主任。Brasky将解决关键的研究差距，这将有助于 了解电子烟对癌症患者的影响，特别是声音的产生 食品和药物管理局的政策决定。该提案要求提供资金，以完成 博士Brasky的研究目标由于COVID-19相关的重大中断。具体目标是：1） 分析184例头颈癌和肺癌患者的观察队列，并检查 电子烟与减少吸烟，戒烟，生活质量和治疗毒性;和，2）评估 pilot patient choice trial of a pilot patient based e-cig vs. 40例计划接受手术切除的头颈癌和肺癌患者的标准治疗。这些 补充研究将是第一批检查与烟草相关癌症患者相关性的研究 并将分享评估措施。这项研究的结果将产生关键数据，以提供 关于电子香烟的健全和循证决定。

TITLE: Electronic Cigarette Use in Head, Neck, and Lung Cancer Patients PROJECT SUMMARY/ABSTRACT The overall goal of this proposal is to facilitate Dr. Theodore Brasky’s development into an established and independent investigator for tobacco control. For this research, he will focus on cancer patients and the impact of electronic cigarettes (e-cigs) on cigarette smoking, quitting, and health outcomes. It is established that cigarette smoking adversely affects the cancer patient in many ways. E-cigs have the potential to reduce cigarette smoke exposures, related toxicities, and foster smoking cessation. However, almost no research exists to substantiate this hypothesis. Dr. Brasky is a cancer epidemiologist and member of the Ohio State University Comprehensive Cancer Center (OSUCCC) with considerable expertise in the analysis and interpretation of longitudinal data. Due to a strong institutional environment, he has been participating in various tobacco-focused research projects over the past several years. Excited by this, he wants to take advantage of the extraordinary opportunities in tobacco control related to e-cigs. The proposed training plan will enable him to obtain expertise and experience in tobacco research (e.g., coursework in tobacco regulatory science), intervention studies (e.g., coursework in clinical research methods and translational behavioral research), and primary data collection in complementary studies. This training will capitalize on the exceptional institutional environment at OSU and an experienced mentor in tobacco control in Dr. Peter Shields, Deputy Director of the OSUCCC. Herein, Dr. Brasky will address critical research gaps that will aid in the understanding for the impact of e-cigs on the cancer patient generally, and specifically for the creation of sound policy decisions by the Food and Drug Administration. This proposal requests a funded extension to complete Dr. Brasky’s research goals due to significant COVID-19 related interruptions. The Specific Aims are to: 1) analyze an observational cohort of 184 head, neck, and lung cancer patients and examine the associations of e-cigs with smoking reduction, smoking cessation, quality of life, and treatment toxicities; and, 2) Evaluate feasibility, acceptability, compliance, and safety of a pilot patient-choice trial of a pod-based e-cig versus standard of care in 40 head, neck, and lung cancer patients planning to undergo surgical resection. These complementary studies will be among the first to examine associations in patients with tobacco-related cancers and will share assessment measures. Results from this research will yield critical data in order to provide sound and evidence-based decisions on e-cigs.